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Introduction
When a half-century ago, anticancer drugs were introduced into clinical practice, their mechanisms of action were not fully elucidated. These chemotherapeutic agents attack DNA, inhibit nucleotide metabolism and supress microtubule function. Yet, conventional chemotherapy can cause remissions and even can cure certain malignancies, such as childhood leukemia and testicular cancer. A conceptual basis for standard chemotherapy was inhibition of cycling and killing of dividing cells. 1 Unrestricted cell cycle is a hallmark of cancer. [2] [3] [4] [5] [6] However, the toxicity to normal cells (especially to proliferating cells) limits chemotherapy. [7] [8] [9] By the beginning of a new millennium, numerous molecular targets of mechanism-based anticancer drugs have been identified. These targets include growth factor (GF) receptors, mitogen-activated kinases, cyclin-dependent kinases and antiapoptotic kinases such as Bcr-Abl and Akt. [10] [11] [12] [13] [14] Although some of them are etiologic to cancer, they are not cancerspecific. With a few exeptions (eg Bcr-Abl), these oncoproteins also govern life and proliferation of normal cells. Besides, cancer cells usually acquire multiple genetic alterations. 15 Parallel and redundant signaling pathways can support survival and growth of cancer cells. 6, 11, 12 Therefore, hitting one target may not be sufficient to kill a cancer cell. It has been suggested that in order to reverse the transformed phenotype, it is desirable to identify an agent capable of affecting multiple targets in signal transduction pathways. 16 The concept of the multi-hit modality is emerging. 11, 12 In light of the multi-hit concept, geldanamycin (GA) and other agents that target heat shock protein-90 (Hsp90) are 'wonder drugs'. The benzoquinone ansamycins GA and herbimycin A, antibiotics produced by yeast, were initially ident- ified as tyrosine kinase inhibitors. However, as it was determined later, the inhibition of kinases by GA and herbimycin A is indirect. In 1986, it has been shown that benzoquinonoid ansamycins have no direct effect on the Src kinase, but instead 'destroy' the intracellular environment. 17 In other words, GA and herbimycin A are not inhibitors of kinases. They target molecular chaperones: Hsp90 and related Grp94.
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Heat shock proteins
By definition, heat induces heat shock proteins (Hsps). Heat shock activates the synthesis of only a few proteins and strongly inhibits the synthesis of most others. 19 Hsp with molecular mass 90 (Hsp90) is an abundant cytosilic protein in bacteria and eukaryotes, with homologues of Grp94 in higher eukaryotes. These two proteins are major targets for Hspactive drugs. 20 Hsps are also referred to as 'molecular chaperones'. A chaperone protein helps other proteins to avoid misfolding pathways that produce inactive or aggregated states. Hsp90 acts in concert with other chaperones and partners (Hsp70, p23, HOP, p50/Cdc) to provide maturation and folding, as well as traficking and function of their client proteins (c-Raf, ErbB-2, steroid receptors). The complexity of multi-chaperone complexes has been extensively reviewed. 20, 21 What is important for clinical applications is that inactivation of Hsp90 results in inappropriate functioning and rapid degradation of chaperone's client proteins. Several protein kinases, including Raf-1, ErbB-2, and Bcr-Abl depend upon the chaperone Hsp90 for proper function and stability. [20] [21] [22] [23] The benzoquinone ansamycins GA and herbimycin A and the macrocyclic antifungal antibiotic radicicol bind to Hsp90 and specifically inhibit this chaperone's function, resulting in degradation of HSP90-associated proteins.
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The proteasome and GA-induced degradation
The ubiquitin (Ub)-proteasome pathway is the major nonlysosomal pathway of proteolysis in human cells and accounts for the degradation of most short-lived proteins. Proteins are usually targeted for proteasome-mediated degradation by the covalent addition of multiple units of the 76 amino acid protein ubiquitin (Ub). Ubiquitinylated proteins are degraded by the 26S proteasome, a large protease complex. Normally, many short-lived proteins, such as cyclins or inhibitors of CDK kinases and wild-type p53, are rapidly degraded by ubiquitindependent proteolysis. 28, 29 In contrast, Hsp90 prevents degradation of Hsp90 client proteins. By inactivating chaperone function, Hsp90-active drugs permit degradation of ErbB-2 and receptors of IGF, insulin, and EGF. 30, 31 The enhanced degradation of receptors can be prevented by inhibitors of the 20S proteasome. 30 For example, within minutes of exposure to GA, mature ErbB-2
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Leukemia became polyubiquitinated. 31 One can predict that the inhibition of the proteasome will result in accumulation of ubiquitinated proteins (Figure 1) . Indeed, treatment of cells with lactacystin, a proteasome inhibitor, blocked GA-induced degradation of ErbB-2 and enhanced the accumulation of polyubiquitinated ErbB-2. Following GA and lactacystin treatment, a higher molecular weight form of ubiquitin-ErbB-2 conjugates was detected. 31 Similarly, cotreatment with the proteasome inhibitor PS-341 reduced GA-mediated degradation of Bcr-Abl. 32 It should be emphasized that inhibition of the proteasome is extremely toxic for a cell. Due to accumulation of certain proteins, inhibitors of proteasome induce apoptosis in leukemia and many non-leukemia cells. [33] [34] [35] GA and PS-341 antagonized each other's toxicity in leukemia cells that were transfected with Bcr-Abl.
32,36
Mutant p53 and geldanamycin
Normally, wt p53 is rapidly degraded by the proteasome. 28, 37 Wt p53 transcriptionally induces Mdm-2, which in turn targets p53 for degradation by the proteasome. 38, 39 Mutant p53 does not induce Mdm-2 and, therefore, mutant p53 is not degraded and is highly overexpressed. In brief, loss of function causes stabilization of mutant p53. 40 Ectopic Mdm-2 still targets mutant p53 for degradation. 41 It has been shown, that GA causes degradation of mutant p53. 42 Inhibition of Hsp90 leads to depletion of mutant p53, but not of wild-type p53 in leukemia, breast and prostate cell lines. 42 GA restores p53 polyubiquitination and degradation of mutant p53 by the proteasome. 43, 44 However, the mechanism of destabilization of mutant p53 appears to be different from the mechanism of destabilization of most GA-sensitive proteins. For one, there is no evidence that mature p53 binds Hsp-90. In contrast, Hsp90 participates in the achievement of the mutated conformation of nascent p53. 45 GA stimulates degradation of a newly synthesized protein only. In agreement, a rate of p53 depletion is slower than those for Raf-1 and ErbB2. Interestingly, mechanisms of depletion of mutant p53 and CFTR appears to be similar. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. 46 Although Mdm-2 plays a small role in the degradation of mutant p53 caused by GA, the alternative mechanism of degradation of mutant p53 still involves ubiquitination and the proteasome. 44 GA does not change levels of wt p53 and does not affect induction of wt p53 by DNA damage, 42 but it prevents wt p53 accumulation caused by paclitaxel.
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Figure 1
Mechanism of action of Hsp90-active drugs. Geldanamycin (GA) causes degradation of Hsp90-client proteins (eg Src). See text for details.
Mapping the network of oncoprotein's targets
G1/S cell cycle transition comprise a highly nonlinear network from activation of growth factor receptors to cyclin dependent kinases. 3, 5 Folding and stability of numerous signaling proteins depend on the Hsp90 function. [20] [21] [22] Receptors of GF that are sensitive to GA-mediated degradation include IGF-I, EGF and PDGF receptors, and HER-2.
30,31,48-50 Hsp90-active agents inactivate multiple kinases such as Src, Lyn, Lck, Raf-1 and Cdk-4.
18,51-53 Akt is affected either in a direct 54 or indirect manner ( Figure 2 ). Inhibition of these pathways results in down-regulation of cyclin D1 and functional inactivation of Cdk-4 ( Figure 2 ). In some cell types, cyclin D expression is dependent upon PI3-kinase and Akt which in turn are inhibited by Hsp90-active agents. 55 Cyclins D are growth factor sensors. 56 Growth factors regulate cyclin D1 by several mechanisms. (1) Transcriptional induction of cyclin D1 that is dependent on the Ras/Raf-1/Mek/ERK pathway. 5 (2) Stabilization and accumulation of the cyclin D protein. In the absence of growth factor signaling, cyclin D1 is rapidly degraded by the proteasome. The pathway that sequentially involves Ras/PI-3 kinase/Akt prevents degradation of cyclin D1. (3) Translocation of cyclin D to the nucleus and its assembly with CDK-4 and CDK-6. 5 All these pathways are blocked by Hsp90-active drugs ( Figure 2 ). In addition, Hsp90-active agents destibilize CDK-4. 53 Like GA and its derivites, radicicol (a macrocyclic antifungal antibiotic) suppresses transformation caused by Src, Ras and Mos. 57, 58 It has been shown that radicicol can inhibit Rasinduced activation of Erk-2.
59 Levels of Raf-1 are decreased in radicicol-treated cells, whereas levels of Ras and Erk-2 remain unchanged. Therefore, like GA, radicicol disrupts v-Src-and Ras-activated signaling pathways by selectively depleting the Raf kinase. 59, 60 As it was discovered later, radicicol binds Hsp90 with consequent dissociation of the Raf/Hsp90 kinase
Figure 2
Hsp90-active drugs disrupt proliferative and antiapoptotic signaling pathways. Molecular targets of Hsp90-active drugs are in bold.
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complex, leading to the attenuation of the Ras/MAP kinase signal transduction pathway. 61 Many other experimental therapeutics are aimed at these signaling network: growth factor receptors and tyrosine kinases, Ras, Mek, PI3-K and CDK. 62, 63 However, downstream and/or parallel signaling pathways may render cancer cells resistant to growth inhibition. Hsp90-active agents destabilize multiple signaling oncoproteins (Figure 2) . By blocking the upstream signaling, GA and herbimycin A inactivate non-target proteins such as Erk1/2. 32,51,64 Although Hsp90-active drugs do not directly target Ras, they block its upstream and downstream signaling pathways. By blocking the Raf-1/MEK pathway, GA abrogated phorbol ester-induced p21 in SKBr3 breast cancer cells 65 and in HL60 leukemia cells. 66 The following example illustrates the importance of targeting parallel pathways. Elevated levels of urokinase plasminogen activator-1 (uPA) and the IGF-I receptor are associated with breast cancer recurrence and decreased survival. IGF-I requires both PI-3K-and MEK-dependent pathways to optimally induce uPA expression. The production of uPA induced by IGF-I was blocked up to 90% by herbimycin A, but was blocked less potently by LY294002 (an inhibitor of PI-3K) or PD98059 (an inhibitor of MEK). 64 All Hsp90-active drugs inhibit the same signaling pathways. For example, the designed small molecule PU3, which competes with GA for Hsp90 binding, induces degradation of proteins, including HER-2, in a manner similar to GA. Furthermore, PU3 inhibits the growth of breast cancer cells causing Rb hypophosphorylation, G1 arrest and differentiation. 67 
Glucocorticoid receptors
Activities of steroid hormones are mediated by the superfamily of nuclear receptors, which include those for steroid and thyroid hormones and retinoids. These receptors are liganddependent transcription factors that can stimulate gene expression and regulate proliferation, differentiation, and specific functions of target tissues. Unligated receptors exist in inactive complexes with chaperone proteins such as heatshock proteins (HSPs). 68 The unliganded glucocorticoid receptor is a complex of a ligand-binding protein, HSP90, HSP70, HSP40, p23 and HOP. 69 Upon binding of glucocorticoids to their receptor, the complex moves along the microtubules to the nucleus. GA disrupts glucocorticoid receptor function. 70 GA impedes hormone-dependent GR translocation along microtubules. 71, 72 A functional antagonism between Hsp90-active agents and glucocorticoids should be taken into account in the therapy of leukemia.
Estrogen and progesterone receptors
Estrogens and progestins control cell proliferation of mammary epithelium. Therefore, anti-estrogens is a tissue-specific therapy in breast cancer. Unstimulated estrogen and progesterone receptors exist as multimolecular complexes consisting of the hormone-binding protein itself and several essential molecular chaperones including Hsp90. Hsp90-active drugs (geldanamycin and radicicol) destabilize these hormone receptors in breast cancer cells. 73 In vivo, administration of 17-allylaminogeldanamycin (17-A-GA) to estrogensupplemented, tumor-bearing mice resulted in marked depletion of progesterone receptor levels in both uterus and Leukemia tumor. It also delayed the growth of hormone-responsive MCF-7 and T47D human tumor xenografts for up to 3 weeks after the initiation of therapy, suggesting that GA can be used in refractory breast cancer. 73 
Mechanisms of growth inhibition
The mechanism of cytotoxicity caused by GA is the degradation of Hsp90-associated proteins. There is a perfect correlation between down-regulation of Hsp90's client proteins and growth inhibition caused by analogs of GA. A nearmaximal depletion of Raf-1, ErbB2 and mutant p53 is accompanied by near-maximally toxicity to SKBr3 breast cancer cells. 16 For GA, these concentrations (IC 80-90 = 30 nM) are between four and five times greater than an IC 50 (below 10 nM). 16 Similarly, 30 nM GA depleted Bcr-Abl in K562 cells. ErbB-2, Raf-1, Cdk-4 and mutant p53 were depleted by GA analogs and KF25706 (a radicicol oxime derivative) at concentrations comparable to those required for the antiproliferative activity. 16, 60 Depletion of the Bcr-Abl protein (at concentrations of GA as low as 30 nM) selectively induced apoptosis in Bcr-Abl positive cells and sensitized these cells to standard chemotherapy.
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Hsp90-active drugs induce both G1 and G2/M phase arrest of the cell cycle. Herbimycin A down-regulates cyclin D, causing an Rb-dependent growth arrest in the G1 phase of the cell cycle. 55, 74, 75 In breast cancer cells, a G1 arrest was accompanied by differentiation and followed by apoptosis. The differentiation was characterized by specific changes in morphology and induction of milk fat proteins and lipid droplets. In cells lacking Rb, neither G1 arrest nor differentiation occurs. Instead, they undergo apoptosis during mitosis. 76 In K562 leukemia cells, GA induces both G1 and G2/M arrests. 36, 77 In these cells, GA down-regulated the expression of cyclin B1 and inhibited phosphorylation of p34Cdc2, causing G2/M arrest. 78 Effects of GA are cell-type dependent. By arresting MCF-7 cells, GA prevents paclitaxel-induced mitotic arrest and Bcl-2 phosphorylation in MCF-7 cells, 79 but not in HL60 cells. 80 Therefore, GA can either decrease or increase the cytotoxicity of paclitaxel, depending on cellular context, that potentially could be exploited therapeutically. Both sequence of drugs and tumor cell biology matters in combining cytotoxics with Hsp90-active drugs. 81 For example, in a subset of breast cancer cell lines, addition of 17-A-GA to cells after exposure to paclitaxel increased apoptosis. In breast cancer cells with intact Rb, such as SKBr3 cells, exposure to 17-A-GA before paclitaxel resulted in growth arrest and abrogated apoptosis. 82 Such a schedule dependence was not seen in BT-549 and MDA-468 breast cancer cells with mutated Rb. Exposure to 17-A-GA before paclitaxel rendered lung cancer cells with low ErbB-2 levels refractory to paclitaxel cytotoxicity. 83 17-A-GA sensitized breast cancer cells to doxorubicin, in a schedule-and Rb-independent manner. 82 In HL60 leukemia cells, Hsp90-active agents diminished the cytotoxicity of doxorubicin. 36 In a cell-type dependent manner, Hsp90-active agents cause apoptosis. For example, 17-A-GA induces cytosolic accumulation of cytochrome C, activates caspase-9 and caspase-3, triggering apoptosis in HL-60/Bcr-Abl and K562 cells. 32 Crucial targets of Hsp90-active drugs vary in different cell types. For example, in Bcr-Abl-expressing K562 leukemia cells, Bcr-Abl appears to be the crucial target which depletion causes cytotoxicity. ErbB-2 is likely an important target in
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SKBr3 breast cancer cells, which overexpress ErbB-2. Contextdependent effects of GA is one of the basis for cancerspecific cytotoxicity.
Bcr-Abl-expressing leukemia
Chronic myelogenous leukemia (CML) is characterized by a reciprocal (t9;22) chromosomal translocation, known as the Philadelphia chromosome, that fuses the truncated Bcr gene to the truncated c-Abl. 84 Bcr-Abl is an active tyrosine protein kinase, which renders cells resistant to apoptosis. [85] [86] [87] [88] Bcr-Abl exists in a complex with Hsp90, and GA causes degradation of Bcr-Abl after 3-5 h of treatment. 77, 89 GA down-regulates Bcr-Abl in natural Ph 1 -positive K562 cells and in HL60 cells transfected with Bcr-Abl. 32, 36, 89 In both cell lines, a depletion of the Bcr-Abl protein and a near-maximal toxicity were achieved at concentrations of GA as low as 30 nM. 36 Furthermore, GA sensitized Bcr-Abl-expressing cells to doxorubicin and, albeit to a lesser degree, to paclitaxel. 36 Specific inhibitors of the Abl kinase, such as STI 571, are very effective in the therapy of Bcr-Abl-positive leukemia, 90, 91 but resistance to STI 571 develops. [91] [92] [93] Hsp90-active drugs, especially in combination with doxorubicin or STI571, may be a second-line therapy of Bcr-Abl-positive leukemias.
FLT3-expressing leukemias
A somatic mutation of the FLT3 gene, in which the juxtamembrane domain has an internal tandem duplication, is found in 20% of human acute myeloid leukemias. Transfection of mutant FLT3 gene into an IL3-dependent murine cell line, 32D, abrogated the IL3-dependency, and caused leukemia in addition to subcutaneous tumors in mice. 94 Herbimycin A, a Hsp90-active agent, inhibited the growth of the transformed 32D cells, but it was ineffective in parental 32D cells. Herbimycin A suppressed the constitutive tyrosine phosphorylation of the mutant FLT3, but not the phosphorylation of the ligandstimulated wild-type FLT3. 95 In mice transplanted with the transformed 32D cells, the administration of herbimycin A prolonged the latency of disease or completely prevented leukemia, depending on the number of cells inoculated and schedule of drug administration. These results suggest that mutant FLT3 is a promising target for Hsp90-active drugs in the treatment of leukemia.
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Selectivity against cancer cells
Two previous examples illustrate the basis of selective killing of ceratin oncoprotein-expressing cells. In addition to Bcr-Abl and FLT3, Raf-1 may be an important target in leukemias. 63 As shown in Bcr-Abl-expressing cells, acute destabilization of the kinase results in cell death. In breast cancer, simultaneous targeting of ErbB-2, the IGF receptor, the Akt kinase, and estrogen receptors by Hsp90-active drugs may be effective. If a cell particularly depends on a certain oncoprotein, it may fall apart following a brief exposure to Hsp90-active drugs.
Secondly, Hsp90 is overexpressed in tumor cells, 96 indicating that these cells are highly dependent on the Hsp90 function. Mutant oncoproteins may depend on the full function of Hsp90 as a conformational buffer to maintain full activity. Overloading of the Hsp90 capacity with mutated oncoproteins under treatment with Hsp90-active agents could cause death of cancer cells. For example, maintenance of wild-type Hck (a Src-family kinase) and its constitutively active counterpart, Hck499F, requires Hsp90. Hck499F had a greater requirement for on-going support from Hsp90 than did mature wild-type Hck. 97 Thirdly, Hsp90-active agents can selectively sensitize oncoprotein-overexpressing cells to chemotherapy. Overexpression of ErbB-2 contributes to chemoresistance. 17-A-GA treatment efficiently depleted ErbB-2 in lung cancer cells. Induction of apoptosis was observed after treatment of cells with the combination of paclitaxel and 17-A-GA. 83 Furthermore, Hsp90-active agents can protect certain cells against chemotherapy. This could be exploited for selective killing of cancer cells.
Besides, anti-HER-2 monoclonal antibody can be used to deliver GA, which depletes HER-2, by coupling GA to these monoclonal antibodies. 98 This might enhance the capacity of the antibody to down-regulate HER-2 and also to avoid sideeffects of GA. 99 In a special case, cancer cells that overexpress quinonemetabolizing enzyme (NQO1), which increases in 17-A-GA growth-inhibition activity, can be more sensitive to this HSP90-active compound.
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Protection against chemotherapy-induced apoptosis
Hsp90-active drugs can protect some cells against apoptosis caused by other anticancer drugs. For example, cultured dorsal root ganglion (DRG) neurons from chick embryos were extremely susceptible to the antineoplastic drugs, cisplatin, vincristine and paclitaxel even in the presence of the neurotrophins. 101 The neurotoxic effects of these anticancer drugs were completely prevented by the addition of low doses of radicicol (20 nM) or GA (2 nM), but higher doses of GA (Ͼ5 nM) had severe cytotoxic effects on neurons. Higher doses of radicicol (500 nM), however, still promoted neurites and prevented apoptosis in the absence of neurotrophins. Slightly different cellular effects of the two antibiotics are not explained.
While potentiating doxorubicin-mediated cytotoxicity in Bcr-Abl-expressing cells, GA protected parental HL60 cells against doxorubicin-induced apoptosis. Combinations of doxorubicin with low concentrations of GA might eliminate Ph-positive cells, while protecting cells that do not express Bcr-Abl. In theory, this can decrease side-effects and increase the therapeutic index.
How can Hsp90-active drugs protect cells from doxorubicin-induced apoptosis? GA and herbimycin A, Hsp90 inhibitors, induce synthesis of Hsp70 and Hsp90. 102, 103 In turn, HSPs can inhibit apoptosis. 20 Induction of Hsp70 by herbimycin A was observed in several cell lines, including A431 human epidermoid carcinoma cells, HeLa S3 cells, chicken embryo fibroblasts, NIH3T3 cells and Rous sarcoma virustransformed NIH3T3 cells. 104 In cardiac cells, herbimycin A induces Hsp70. Moreover, Hsp's induction correlated with the ability of herbimycin A to protect cells against severe stress. These results indicate the possibility of a pharmacological approach to Hsp70 induction and cardiac protection, which may ultimately be of clinical relevance. 105 
Effective concentrations in vivo
Concentrations of Hsp90-active drugs that deplete Hsp90-associated oncoproteins can be achieved and tolerated in SPOTLIGHT vivo. Given that GA displayed hepatotoxicity in dogs which appears to be unrelated to its Hsp90 antagonism, 17-allylamino,17-demethoxygeldanamycin (17-A-GA), a geldanamycin analog, is the first inhibitor of Hsp90 that enters a phase I clinical trial in cancer. 81 In mice, bolus i.v. delivery of 60 mg/kg 17-A-GA produced 'peak' plasma 17-A-GA concentrations between 5.8 and 19.3 g/ml 5 min after injection. After i.v. bolus delivery to mice, 17-A-GA distributed rapidly to all tissues, except the brain. Substantial concentrations of 17-A-GA were measured in each tissue. A 60 mg/kg dose of 17-A-GA, caused no changes in appearance, appetite, waste elimination, or survival of treated animals.
106
Phase I clinical trials
Although few data are available, one can certainly expect that Hsp90-active agents should be toxic to normal cells. It has been shown, for example, that by inhibiting the Raf-1/MAPK pathway, GA induced apoptosis in luteinized granulosa cells. 107 In clinical trials, one can retrospectively analyze side-effects due to toxicity to normal cells, thus revealing dose-limiting targets in proliferating (eg mucosa and bone marrow cells) and non-proliferating normal cells. This in turn can help to design rational therapeutic modalities. In a clinical trial at the National Cancer Institute (NIH), 17-allylamino,17-demethoxygeldanamycin (17-A-GA) was administered daily by 1-h infusion for 5 days every 3 weeks in adult patients with various solid tumors.
108 Dose-limiting toxicity was reversible grade III hepatotoxicity. Other grade I/II toxicities included fever, emesis, anemia and fatigue. The maximum tolerated dose was 40 mg/m 2 and plasma maximal concentrations levels were 1860 ± 660 nM. The recommended 17-A-GA phase II dose on this schedule is 40 mg/m 2 , at which inhibition of the target Hsp90 occurs. 108 In the clinical trial at Memorial Sloan Kettering in New York, the drug was administered daily for 5 days and repeated every 3 weeks. At 80 mg/m 2 dose (with peak plasma levels of the drug: 2700 nM), limiting toxicities were diarrhea, thrombocytopenia and transient transaminitis. 109 This study suggests that 17-AAG can be administered to patients in concentrations exceeding those that were effective in pre-clinical models. 109 In a phase I trial at Royal Marsden Hospital (UK), with weekly administrations at doses of 80 mg/m 2 , no hematological or biochemical toxicity has been observed. In this study, the evidence of biological activity has been demonstrated by induction of Hsp70 in PBLs at 6 h. In the data available by 2001, no objective responses were seen, 109, 110 however four of 13 patients had stable disease beyond 3 months. 109 Two conclusions could be drawn. Firstly, a Hsp90-active drug is not a 'magic bullet' against cancer. Secondly, by shortening the duration of a treatment (1 day instead of 5 days), one may eliminate side-effects. This could be expected. Unlike DNA-damaging drugs, Hsp90-active drugs do not cause irreversible damage, if the time of exposure is brief. Therefore, cells that have not undergone apoptosis potentially may recover.
Although Hsp90-active drugs are introduced in the therapy of solid tumors, preclinical data indicate great promise for these drugs in therapy of leukemia. In striking symmetry, STI571, which was designed to treat Bcr-Abl-expressing leukemia, is underway to explore its utility in solid tumors harboring c-kit and PDGFR abnormalities. The drug novobiocin has clinically been used for a decade. Coumarin antibiotics, including novobiocin, are known as inhibitors of topoisomerase II. In addition, novobiocin is used clinically as a modulator of alkylating agents. 111 Besides, novobiocin reverses drug resistance and increases intracellular accumulation of etoposide. 112 Novobiocin (300 M) induces granulocytic differentiation in HL-60 cells. 113 Finally, at doses of 300-800 M, novobiocin depleted cells of Raf-1, ErbB2, mutant p53 and v-Src. 114 Although novobiocin binds to a site on Hsp90 that is different from the geldanamycin-binding site, it, like GA, is able to inhibit the chaperone function of Hsp90 and to deplete tumor cells of Hsp90-dependent proteins. 114 Novobiocin therapy decreased levels of Raf-1 in murine splenocytes, indicating that mechanism-based concentration is achievable. 114 Following administration of novobiocin to patients, the serum drug concentration vary between 100 and 400 g/ml,
115 which corresponds to doses that down-regulate Hsp90-associated proteins in vitro.
Thus, the Hsp90-active agent novobiocin is already used in cancer therapy. Side-effects and maximum tolerated dose of novobiocin are difficult to evaluate because the drug was administered in combination with other cytostatics. 111 Given that the severity of mucositis correlated with the plasma levels of novobiocin, 111 one can conclude that novobiocin inhibits proliferation of normal epithelial cells.
It was believed that inhibitors of DNA repair (eg novobiocin) can overcome resistance to alkylators which damage DNA. 111 Ironically, inhibition of DNA repair facilitates development of resistance to alkylating agents. 116 It is tempting to suggest that, by inhibiting Hsp90 functions (rather than DNA repair), novobiocin sensitizes certain tumors to chemotherapy.
